Skip to main content

Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis

Abstract

Summary

Among 95,057 patients ≥50 years with new anti-osteoporosis medications (AOM) (2001–2013) in primary care, 1-year cessation was 51% (28%–68%), higher in men, smokers, patients with missing lifestyle data, and out normal BMI, and lower in those aged 60–79, with recent fractures or other anti-osteoporotics, suggesting non-severe osteoporosis and less risk awareness.

Purpose

Low compliance to anti-osteoporosis medications (AOM) has been previously reported. We aimed to estimate 1-year cessation rates of different AOMs as used in Spanish healthcare settings, and to identify associated risk factors.

Methods

A cohort study was performed using primary care records data (BIFAP). Patients entered the cohort when aged 50 years in 2001–2013, with ≥1 year of data available, and identified as incident users of AOM (1-year washout). Participants were divided into six cohorts: alendronate, other oral bisphosphonates, selective oestrogen receptor modulators, strontium ranelate, teriparatide, and denosumab. Patients were followed from therapy initiation to the earliest of cessation (90-day refill gap), switching (to alternative AOM), loss to follow-up, death, or end of 2013. One-year therapy cessation was estimated using life tables. Hazard ratios (of cessation) according to age, sex, lifestyle factors, morbidity, and co-medication were estimated after stepwise backwards selection.

Results

A total of 95,057 AOM users were identified (91% women; mean age 68). One-year cessation was 51% overall, highest for strontium ranelate (68%), and lowest for denosumab (28%). Cessation probability was higher in men (14% to 2.1-fold), smokers (>6%), and patients with missing BMI (19–28%) or smoking (6–20%) data, and overweight/obese/underweight (7% to 2.6-fold increase compared to normal weight). Patients aged 60–79 years, with a recent fracture or other drugs used for osteoporosis, had better persistence.

Conclusions

Over half of the patients initiating AOM stopped therapy within the first year after initiation. The described risk factors for cessation could be proxies for non-severe osteoporosis, and/or disease/risk awareness, which could inform the targeting of high-risk patients for monitoring and/or interventions aimed at improving persistence.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996 Dec 7) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet Lond Engl 348(9041):1535–1541

    CAS  Article  Google Scholar 

  2. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al (2000 Nov) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124

    CAS  Article  PubMed  Google Scholar 

  3. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al (1999 Aug 18) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645

    CAS  Article  PubMed  Google Scholar 

  4. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al (2004 Jan 29) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468

    CAS  Article  PubMed  Google Scholar 

  5. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009 Apr) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res Off J Am Soc Bone Miner Res 24(4):719–725

    CAS  Article  Google Scholar 

  6. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al (2005 Aug) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res Off J Am Soc Bone Miner Res 20(8):1315–1322

    CAS  Article  Google Scholar 

  7. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001 May 10) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441

    CAS  Article  PubMed  Google Scholar 

  8. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155

    Google Scholar 

  9. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD004523

    Google Scholar 

  10. Reyes C, Pottegård A, Schwarz P, Javaid MK, Van Staa TP, Cooper C, et al. 2016 Real-life and RCT participants: alendronate users versus FITs’ trial eligibility criterion. Calcif Tissue Int.

  11. Siris ES, Selby PL, Saag KG, Borgström F, Herings RMC, Silverman SL (2009 Feb) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3–13

    Article  PubMed  Google Scholar 

  12. Carbonell-Abella C, Pages-Castella A, Javaid MK, Nogues X, Farmer AJ, Cooper C et al (2015 Jul) Early (1-year) discontinuation of different anti-osteoporosis medications compared: a population-based cohort study. Calcif Tissue Int 23

  13. Tosteson ANA, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM et al (2003 Aug 15) Early discontinuation of treatment for osteoporosis. Am J Med 115(3):209–216

    Article  PubMed  Google Scholar 

  14. Penning-van Beest FJA, Goettsch WG, Erkens JA, Herings RMC (2006 Feb) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28(2):236–242

    CAS  Article  PubMed  Google Scholar 

  15. Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R et al (2004 Feb) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26(2):245–256

    Article  PubMed  Google Scholar 

  16. Salgueiro ME, Manso G, Castells X, Jimeno FJ, Ordoñez L, González V et al (2013 Jan) Trends in the pharmacological treatment of osteoporosis in Spain from 2000 to 2008. Maturitas 74(1):74–78

    CAS  Article  PubMed  Google Scholar 

  17. White HJ, Bettiol SS, Perera R, Roberts NW, Javaid MK, Farmer AJ (2010 Dec) A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture. Fam Pract 27(6):593–603

    CAS  Article  PubMed  Google Scholar 

  18. BIFAP 2015, Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria [Internet]. [cited Sep 15]. Available from: http://www.bifap.org/

  19. World Organisation of National Colleges, Academic & Academic Associations of General Practitioners/Family Physicians (1998). The international classification of primary care. Oxford: Oxford University Press.

  20. Gardarsdottir H, Souverein PC, Egberts TCG, Heerdink ER (2010 Apr) Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 63(4):422–427

    Article  PubMed  Google Scholar 

  21. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414–2419

    Article  PubMed  Google Scholar 

  22. Vicente Molinero A, Lou Arnal S, Medina Orgaz E, Muñoz Jacobo S, Antonio Ibáñez Estrella J (2011 Feb) Osteoporosis treatment with biphosphonates: approaches to care reality. Atencion Primaria Soc Esp Med Fam Comunitaria. 43(2):95–99

    Article  Google Scholar 

  23. de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T (2010 Nov) Clinical characteristics of patients under treatment for osteoporosis in a primary care centre. Who do we treat? Atencion Primaria Soc Esp Med Fam Comunitaria 42(11):559–563

    Article  Google Scholar 

  24. Roerholt C, Eiken P, Abrahamsen B (2009 Feb) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 20(2):299–307

    CAS  Article  Google Scholar 

  25. Imaz, I. (2010) Análisis coste-utilidad de los tratamientos farmacológicos para la prevención de frac- turas en mujeres con osteoporosis en ESPAÑA. Madrid: Agencia de Evaluación de Tecnologías Sanitarias (AETS). Instituto de Salud Carlos III- Ministerio de Ciencia e Innovación

  26. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM (2010 Nov) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 21(11):1943–1951

    CAS  Article  Google Scholar 

  27. Harrington JT, Ste-Marie L-G, Brandi ML, Civitelli R, Fardellone P, Grauer A et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74(2):129–135

    CAS  Article  PubMed  Google Scholar 

  28. Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D et al (2004 Apr) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20(4):433–439

    CAS  Article  PubMed  Google Scholar 

  29. European Medicines Agency. 2016 PSUR assessment report. Strontium ranelate. EMA/PRAC/136656/2013 [Internet]. 2013 [citedJun 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500147168.pdf

  30. Agencia Española de Medicamentos y Productos Sanitarios (2007). Ranelato de estroncio (Osseor®, Protelos®): Riesgo de reacciones graves de hipersensibilidad [Internet]. [cited 2016 May 6]. Available from: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2007/NI_2007-17_protelos-osseor.htm

  31. Agencia Española de Medicamentos y Productos Sanitarios - La AEMPS Informa - Notas informativas - Medicamentos de Uso Humano. Ranelato de estroncio (Osseor®, Protelos®): riesgo de tromboembolismo venoso y reacciones dermatológicas graves. Nuevas contraindicaciones de uso [Internet]. (2012) [cited 2016 May 6]. Available from: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2012/NI-MUH_04-2012.htm

  32. Agencia Española de Medicamentos y Productos Sanitarios. Ranelato de estroncio (▼Osseor®, ▼Protelos®): la revisión europea concluye que el balance beneficio-riesgo es desfavorable [Internet]. Agencia Española de Medicamentos y Productos Sanitarios; [cited 2015 Jul 28]. Available from: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2014/NI-MUH_FV_01-2014-ranelato-estroncio.htm

  33. Agencia Española de Medicamentos y Productos Sanitarios. Ranelato de estroncio (▼Osseor®, ▼Protelos®): calificado como medicamento de diagnóstico hospitalario [Internet]. Agencia Española de Medicamentos y Productos Sanitarios; [cited 2015 Jul 28]. Available from: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2014/NI-MUH_FV_09-2014-ranelato.htm

  34. Agencia Española de Medicamentos y Productos Sanitarios. Bisfosfonatos de administración parenteral y osteonecrosis del maxilar [Internet]. 2005 [cited 2016 Apr 12]. Available from: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2005/NI_2005-17_bisfosfonatos_osteonecrosis.htm

  35. Agencia Española de Medicamentos y Productos Sanitarios. Recomendaciones para la prevención de la osteonecrosis del maxilar asociada al tratamiento con bisfosfonatos [Internet]. 2009 [cited 2015 Dec 16]. Available from: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2009/NI_2009-10_bisfosfonatos.htm

  36. Agencia Española de Medicamentos y Productos Sanitarios. Denosumab (Prolia®, ▼Xgeva®): riesgo de osteonecrosis mandibular e hipocalcemia [Internet]. 2014 [cited 2015 Dec 16]. Available from: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2014/NI-MUH_FV_13-2014-Denosumab.htm

  37. Aizpurua I, Álvarez M, Echeto A, Etxebarria I, Fernández J, Gardeazabal MJ, et al. Consenso sobre la Osteoporosis postmenopaúsica en la CAPV - Enero 2015 [Internet]. 2015 Jan [cited 2016 Dec 16]. Available from: http://www.osakidetza.euskadi.eus/contenidos/informacion/publicaciones_informes_estudio/es_pub/adjuntos/Consenso%20Osteoporosis_2015_es.pdf

  38. Klop C, Welsing PMJ, Elders PJM, Overbeek JA, Souverein PC, Burden AM et al (2015) Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int 26(6):1831–1840

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. Amaya MC, Gómez MM, Martínez MJ, Lendínez JM. Adecuación del tratamiento preventivo de fracturas osteoporóticas en mujeres posmenopáusicas. SEMERGEN - Med Fam. :121–7.

  40. Cantudo-Cuenca MR, Calvo-Cidoncha E, Robustillo-Cortés MA, Saborido-Cansino MC, Gómez-Estrella G, Sánchez-Pedrosa A (2016 Jan) Suitability of strontium ranelate in a health care management area after drug surveillance alerts. Aten Primaria 48(1):49–53

    CAS  Article  PubMed  Google Scholar 

  41. Carbonell AC (2011 Jun) La osteoporosis en Atención Primaria. Rev Osteoporos Metab Miner. 3(2):73–74

    Google Scholar 

  42. Blanch J, Casado E, González J, Valdés C, Ruiz-Baena J, Palomino R et al (2016 Mar) Percepción de los profesionales médicos respecto la adherencia terapéutica de los pacientes con osteoporosis. Rev Osteoporos Metab Miner 8(1):15–23

    Google Scholar 

  43. Gifre L, Monegal A, Filella X, Muxi A, Guañabens N, Peris P (2015). Factores relacionados con la respuesta inadecuada al tratamiento osteoformador (teriparatida/PTH 1–84) en pacientes con osteoporosis severa. Resultados preliminares. Rev Osteoporos Metab Miner [Internet]. [cited 2016 Dec 19]; Available from: http://www.redalyc.org/articulo.oa?id=360943612002

  44. Kearney DM, Lockey RF (2006) Osteoporosis and asthma. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 96(6):769–774 778, 857

    Article  Google Scholar 

Download references

Acknowledgements

Authors would like to acknowledge the excellent collaboration of general practitioners and paediatricians and the support of regional governments taking part in BIFAP.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elisa Martín-Merino.

Ethics declarations

Conflicts of interest

DPA’s research group has received unrestricted research grants from Servier Laboratoires, UCB Pharma, and AMGEN. All other authors declare that they have no conflict of interest. The views expressed here do not necessarily represent the views of the co-authors’ respective organizations.

Funding

N/A.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Martín-Merino, E., Huerta-Álvarez, C., Prieto-Alhambra, D. et al. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos 12, 39 (2017). https://doi.org/10.1007/s11657-017-0331-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11657-017-0331-6

Keywords

  • Anti-osteoporosis medication
  • Cessation
  • Risk factors
  • Primary care